Vivos Therapeutics, Inc.

Good day, everyone, and welcome to the Vivos Therapeutics first quarter 2023 earnings conference call. At this time, participants are in listen-only mode. A question and answer session will follow management's remarks. This conference call is being recorded, and a replay of today's call will be available on the investor relations section of Vivos' website and will remain posted there for the next 30 days. I will now hand the call over to Julie Gannon, Vivos' investor relations officer, for introductions and the reading of the safe harbor statement. Please go ahead.

Thank you, operator. Hello, everyone, and welcome to our conference call. A copy of our earnings press release is available on the investor relations section of our website at www.vivos.com. With us on today's call are Kirk Huntsman, Vivos chairman and chief executive officer, and Brad Ammon, chief financial officer. Today we'll review the highlights and financial results for the first quarter of 2023 as well as more recent developments and vivos plans for the remainder of 2023. Following these formal remarks, we will be happy to take questions. I would also like to remind everyone that today's call will contain certain forward-looking statements from our management made within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21 of the Securities and Exchange Act of 1934, as amended, concerning future events. Words such as aim, may, could, should, projects, expects, intends, plans, believes, anticipates, hopes, estimates, goals, and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve significant known and unknown risks and are based upon a number of assumptions and estimates which are inherently subject to significant risks, uncertainties, and contingencies, and many of which are beyond the company's control. Actual results, including without limitation, the results of Devo's growth strategies, operational plans, including sales, marketing, product acquisition, and integration, Research and development, regulatory initiatives, cost savings plans, and plans to generate revenue, as well as future potential results of operations or operating metrics, such as potential for future positive cash flows and other matters to be addressed by vivos management in this conference call, may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the risk factors described and other disclosures contained in VIVO's filings with the Security and Exchange Commission, including the risk factors and other disclosures in our Form 10-K for the year ended December 31, 2022, and our other filings with the SEC, all of which are or will be accessible on the Investor Relations section of vivos website as well as the SEC's website. Except to the extent required by law, vivos assumes no obligation to update statements as circumstances change. Finally, please be aware that the U.S. Food and Drug Administration has given certain vivos appliances 510 clearance to treat mild to moderate OSA. Any reference herein regarding vivos treatment or the vivos method should be viewed in that context. Treatment of patients with severe OSA is performed off-label at the sole clinical discretion of the treating doctor and is not part of the vivos treatment protocol. Now, at this time, it is my pleasure to introduce Kirk Huntsman, Chairman and CEO of vivos. Kirk, please go ahead.

Thank you, Julie. I want to thank you all for joining us on today's conference call. Just a moment, I'll turn the call over to our Chief Financial Officer, Brad Ammon, who will walk you through the highlights of our first quarter 2023 financial and operating results. Once Brad is finished, I'll come back on and speak with you about the highlights of what we accomplished at Vivos during the first quarter and in the past few weeks following the quarter end, including our acquisition of product rights and patents from Advanced Facial Dontics. This has expanded our product portfolio even further, allowing vivos trained providers to treat a much larger percentage of their patients, which ultimately increases the revenue potential for vivos. I'll also talk about our progress with the FDA, as well as ongoing R&D efforts. In more recent news, I'll talk about some of the actions we took to improve our organizational infrastructure and highlight how we took steps to increase operational efficiencies, reduce expenses, and position us to take advantage of the growth opportunities that are available to us. I'm pleased to say that due to these initiatives, we can reiterate that we remain on target to achieve our goal of positive cash flow for the first quarter of 2024, which is a full quarter earlier than the target we provided you on our last earnings call in March. Our goal is to achieve this key target without having to raise any further equity capital if possible. Following that, I'll talk about our plans going forward in 2023 how we intend to build upon what we've already done, and what we have planned for the rest of the year, as well as into 2024. After that, we'll take your questions. Now, let me turn it over to Brad to review our financials. Brad, please go ahead.